Skip to main navigation

Patients & Families
Healthcare Providers
Investors & Media

Our Science
Our Pipeline
Our Company
Our Partnerships
Life at C4T

Our Science
Our Pipeline
- Overview
- Cemsidomide
- CFT8634
- CFT8919
Our Partnerships
Who We Are
Life at C4T

Patients & Families
Healthcare Providers
Investors & Media

Overview
Press Releases
Events & Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Email Alerts
Contact IR
FAQs

Scientific Publications

Presentations

Phase 1/2 Study of CFT1946, a Novel BiDAC Degrader Targeting Mutant BRAF V600X Solid Tumors Including Metastatic Colorectal Cancer (CRC) in Combination with Cetuximab

Source:

ESMO Gastrointestinal Cancers Congress 2024

CFT7455: A novel IKZF1/3 degrader, demonstrates potent anti-tumor activity in peripheral and CNS models of non-Hodgkin’s lymphoma as a single agent or in combination with clinically approved agents

Source:

17th Annual International Conference on Malignant Lymphoma, June 2023

The Discovery and Characterization of CFT1946: A Potent, Selective, and Orally Bioavailable Degrader of Mutant BRAF for the Treatment of BRAF-driven Cancers

Source:

AACR Annual Meeting 2023

TPD Summit: Monofunctional Degradation Activating Compounds (From New Targets to the Clinic)

Source:

TPD Summit, October 2022

Discovery on Target: Monofunctional Degradation Activating Compounds

Source:

Discovery on Target, October 2022

Preclinical Evaluation of CFT1946 as a Selective Degrader of Mutant BRAF for the Treatment of BRAF Driven Cancers

Source:

AACR Annual Meeting 2022

The Discovery and Characterization of CFT7455: A Potent and Selective Degrader of IKZF1/3 for the Treatment of Relapsed/Refractory Multiple Myeloma

Source:

AACR Annual Meeting 2022

The Discovery and Characterization of CFT8634: A Potent and Selective Degrader of BRD9 for the Treatment of SMARCB1-perturbed Cancers

Source:

AACR Annual Meeting 2022

AACR Poster Presentation: CFT7455 Phase 1/2 Cohort A

Source:

AACR Annual Meeting 2022

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

Source:

63rd ASH Annual Meeting & Exposition

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Scientific Publications

More information is coming soon.

Image Description

617-231-0700
info@c4therapeutics.com

490 Arsenal Way, Suite 120
Watertown, MA 02472

© 2026 C4 Therapeutics, Inc., Inc.

Privacy Policy
Terms of Use Agreement

You are now leaving c4therapeutics.com

You are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.

No, I want to stay Yes, I want to Proceed to the Other Site

You are now leaving c4therapeutics.com

You are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.

No, I want to stay Yes, I want to Proceed to the Other Site